The global gastroretentive drug delivery systems market size is expected to reach USD 22.7 billion by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently. Hence enhancing absolute bioavailability and maximizing its absorption is expected to boost market growth during the forecast period.
Several advantages of these DDSs include curative efficiency and an increase in the bioavailability of drugs. The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site. It also offers higher efficiency owing to reduced counter activity by the body. Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.
The DDS sustains the release of drugs and avails local therapy in the small intestine and stomach. The method is useful in the treatment of various disorders related to the small intestine and stomach. Rising cases of stomach and small intestine-related disorders are anticipated to foster the demand for such efficient DDSs. According to the Endoscopy Center, each year around 62.0 million people are diagnosed with digestive disorders. The prevalence of most digestive disorders increases with age, creating demand for novel healthcare systems among adults and the geriatric population.
These DDSs are effective in treating duodenal and gastric ulcers, including esophagitis, by eliminating deeply buried helicobacter pylori from the submucosal tissue of the stomach. Apart from this, GRDDSs release the medicine slowly in the stomach and preserve its effective concentration in systemic circulation for a prolonged period of time. Hence, the above-mentioned factors are predicted to augment market expansion.
Request a free sample copy or view report summary: Gastroretentive Drug Delivery Systems Market Report
The floating drug delivery systems held the largest market share in 2024.
These systems have a lower density than gastric fluids and hence stay buoyant in the stomach without altering the gastric emptying rate for a long time.
The liquid dosage form segment is expected to grow at the fastest rate during the forecast period due to the availability of a wide range of liquid-based gastroretentive products in treating all types of gastric disorders.
The online pharmacies segment is predicted to witness the fastest growth rate over the forecast timeframe as they offer a wide range of options along with in-depth drug information.
North America held the largest market share and is anticipated to maintain its dominance over the forecast period.
This is attributable to the growing prevalence of H. Pylori infection, increasing R&D expenditure, and rising technological advancements in gastroretentive DDSs.
Grand View Research has segmented the global gastroretentive drug delivery systems market based on type, dosage, distribution channel, and region:
Gastroretentive Drug Delivery Systems Type Outlook (Revenue, USD Million, 2018 - 2030)
Floating Drug Delivery System
Expandable Drug Delivery System
Bioadhesive Drug Delivery System
High Density Systems
Others
Gastroretentive Drug Delivery Systems Dosage Outlook (Revenue, USD Million, 2018 - 2030)
Tablets
Capsule
Gel
Liquid
Others
Gastroretentive Drug Delivery Systems Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Gastroretentive Drug Delivery Systems Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Gastroretentive Drug Delivery Systems Market
Catalent, Inc
Lonza
Evonik Industries AG
Colorcon
Quotient Sciences
AptarGroup, Inc.
Aenova Holding GmbH
Evotec SE
Vectura Group Ltd
Ashland
"The quality of research they have done for us has been excellent..."